温州地区汉族人群CYP2C19和CYP2C9基因多态性分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2803 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate distribution status of CYP2C19 and CYP2C9 genotype in Wenzhou Han population. Methods: The CYP2C19 and CYP2C9 genotype of 287 Wenzhou Han Chinese were determined by sequencing. Results: In Wenzhou Han population, CYP2C19*1, CYP2C19*2 and CYP2C19*3 allele frequencies were 65.16%, 29.27% and 13.6%, respectively; CYP2C19*1/*1, CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*3, CYP2C19*2/*2 and CYP2C19*3/*3 genotype frequencies were 44.95%, 33.45%, 6.97%, 4.18% and 0.00%, respectively. The frequency of CYP2C19 poor metabolisms was 14.63%; CYP2C9*1 and CYP2C9*3 allele frequencies were 97.74% and 2.26%, respectively; CYP2C9*1/*1 and CYP2C9*1/*3 genotype frequencies were 95.47% and 4.53%, respectively, CYP2C9*3/*3 homozygous genotype was not found in this study. Conclusion: The frequencie of CYP2C19 and CYP2C9 poor metabolisms are similar to those of Japanese population, whereas they are significantly different from America-European populations.

Key words： cytochrome P450 CPY2C19 CYP2C9 polymorphism Wenzhou Han population

Received: 05 May 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Huaibin
	WANG Jindan
	HU Lihuai
	WEN Chaowei
	LV Jianxin.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I12/864

[1]de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-me-phenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22): 15419-15422.
[2]Bae JW, Kim HK, Kim JH, et al. Allele and genotype frequencies of CYP2C9 in a Korean population[J]. Br J Clin Pharmacol, 2005, 60(4): 418-422.
[3]蔡晓青, 周莹, 黄丽丹, 等. 华法林和拜阿司匹林预防血液透析长期深静脉导管血栓形成的作用[J]. 温州医学院学报, 2013, 43(12): 823-825.
[4]Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the antico-agulant response to warfarin: prlposal for a new dosing regimen in Chinese patients[J]. Eur J Clin Pharmacol, 2007, 63(12): 1135-1141.
[5]夏东亚, 左金梁, 赵东祥, 等. 中国汉族和蒙古族健康人药物代谢酶CYP3A4、CYP2C9、CYP2C19、CYP2D6基因多态性分析[J]. 中国药学杂志, 2012, 47(24): 2017-2022.
[6]顾连云, 赵萍. CYP2C19基因多态性在江苏及其周边地区汉族人群的调查研究[J]. 实用临床医药杂志, 2011, 15(1): 125-128.
[7]Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenyt-oin 4’-hydroxylation in an extend Japanese population[J].Clin Pharmacol Ther, 1996, 60(6): 661-666.
[8]Dai DP, Xu RA, Hu LM, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database[J]. Pharmacogenomics J, 2014, 14(1): 85-92.
[9]Buzoianu AD, Trifa AP, Muresanu DF, et al. Analysis of CYP2C9*2, CYP2C9*3 and VKORC1-1639 G>A polymor-phisms in a population from South-Eastern Europe[J]. J Cell Mol Med, 2012, 16(12): 2919-2924.
[10]Garcia-Martin E, Martinez C, Ladero JM, et al. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population[J]. Eur J Clin Pharmacol, 2001, 57(1): 47-49.
[11]Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population[J]. Pharmacogenetics, 1997, 7(5): 405-409.